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ABSTRACT
Procalcitonin is a sensitive and specific marker
of bacterial infection; low results allow
clinicians to safely de-escalate antibiotics. This
retrospective cohort study aimed to determine
the effect of low procalcitonin results on
withholding, discontinuing, or de-escalating
antibiotics in hospitalized patients at a tertiary
care center. Antibiotics were initiated or
continued without de-escalation in 55% of
patients with low procalcitonin results. Among
patients with low procalcitonin results, the
primary service, but not measures of patient
complexity, disease severity, or underlying
disease process (lower respiratory tract
infection evaluation versus systemic
inflammatory response syndrome/possible
sepsis) was associated with initiation or
continued broad-spectrum antibiotic use.
Provider-level factors may be an important
variable in the initiation or continued use of
broad-spectrum antibiotics for patients with
low procalcitonin levels.
Keywords: Antibiotic stewardship; Behavioral
sciences; Discordance; Procalcitonin
INTRODUCTION
Procalcitonin is highly sensitive and specific for
bacterial infections [1–3]. Low procalcitonin
results support clinician decisions to withhold,
discontinue or de-escalate antibiotics safely,
especially in the evaluation of lower
respiratory tract infection or patients with
systemic inflammatory response syndrome
(SIRS)/possible sepsis [4–6]. International
studies, largely centered in Europe,
demonstrate high overall concordance
between procalcitonin algorithms and
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antibiotic use [5, 6]. However, antibiotic use
stratified by low versus high procalcitonin result
is lacking, especially among hospitalized
patients in the USA. This study aimed to
determine the association between low
procalcitonin results and withholding,
discontinuation, or de-escalation of antibiotics
in patients hospitalized at a US tertiary care
center with an existing procalcitonin guideline.
Additionally, as procalcitonin-based algorithms
are not intended to override clinical decision
making by the provider, we aimed to
understand better which factors may impact
the decision of a provider to continue antibiotic
therapy despite a low procalcitonin test result.
METHODS
Study Design and Population
This was a retrospective cohort study of all adult
patients admitted to a US tertiary care center
(University of Wisconsin Hospital and Clinics)
between November 1 and December 31, 2014
who had procalcitonin ordered as part of their
hospitalization. The hospital’s procalcitonin
guideline was in effect for 9 months prior to
the study start date. The guideline was
developed by the Antimicrobial Use
Sub-Committee (AMUS) of the Pharmacy and
Therapeutics Committee at the University of
Wisconsin Hospital and Clinics. The guideline
was distributed to all inpatient providers and
the AMUS members held educational didactics
with each inpatient physician group during the
initial 6 months of the roll-out period. It is
important to note during the study period a lab
order for procalcitonin was not pre-selected
(e.g. part of an order set) for any patient and
therefore the provider must have specifically
chosen to order the test. The guideline suggests
ordering a baseline procalcitonin for patients
with suspected lower respiratory tract infection
and/or evidence of SIRS/possible sepsis [7]. For
patients with values\0.25 ng/ml, the guideline
suggests continuing to withhold antibiotic
therapy or to consider de-escalation or
discontinuation if antibiotics have already
been initiated. As is consistent with other
procalcitonin guidelines, our guideline also
includes the caveat that procalcitonin result
should not trump clinician decision making.
The University of Wisconsin Institutional
Review Board deemed this study exempt from
review and waived the need for written
informed consent. This article does not
contain any new studies with human or
animal subjects performed by any of the
authors.
Data Collection
Data were abstracted retrospectively from
provider notes, laboratory results, and the
medication administration record, all of which
were available in the hospital’s electronic
medical record system. The dependent variable
was antibiotic discordance, determined based
on active antibiotic prescriptions C48 h after
the procalcitonin result became available.
Discordance was defined as (1) initiation or
continued use of antibiotics without
de-escalation or discontinuation in the setting
of a low procalcitonin result or (2)
discontinuation of antibiotics in the setting of
a high procalcitonin result. The independent
variable of interest was whether the patient had
a low procalcitonin result, defined as\0.25 ng/
mL. Other variables obtained from the medical
record included age, gender, whether the
patient had been hospitalized in the past
30 days, primary service caring for the patient,
and the underlying clinical reason (i.e., lower
respiratory tract infection, SIRS/possible sepsis,
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or other) for ordering the test. The 3 MTM All
Patient Refined DRG Classification system
(APR-DRG) (3 MTM Health Information
Systems, Salt Lake City, UT, USA) was used to
measure disease severity, while the Charlson
Comorbidity Index was used to capture patient
complexity [8]. Both were calculated using
billing codes (International Classification of
Diseases, Ninth Revision, World Health
Organization, Geneva, Switzerland).
Statistics
Descriptive statistics were used to report the
proportion and means of patient- and
provider-level variables. Pearson’s Chi-squared
test and univariate odds ratio were used to
examine whether the proportion of patients
receiving discordant antibiotics varied based on
low versus high procalcitonin results. Among
the low procalcitonin subgroup, univariate odds
ratios were calculated to assess patient- and
provider-level factors that may be associated
with discordant antibiotic use. Multivariate
modeling was attempted, but the sample size
precluded an adequate mathematical fit. All
statistics were calculated using STATA (ver. 12;
StataCorp LP, College Station, TX, USA).
RESULTS
All 181 hospitalized patients who underwent
procalcitonin testing during the 2-month study
period were included in the analysis, and cohort
characteristics are presented in Table 1. Half of
them (n = 91) had low procalcitonin levels. The
average patient age was 60 years, and 69/181
(38%) were female. Thirty-two patients (18%)
had been hospitalized in the past 30 days. The
mean APR-DRG weighted value was 2.77
(0.28–17.75). This compares to a median
weight of all patients admitted to the
University of Wisconsin Hospital and Clinics
for 2014 at 1.14 and 75th percentile at 2.02. The
mean Charlson Comorbidity score was 2.54
(0–8). Patients were cared for by the following
services: medicine 47%, critical care 33%,
immunocompromised 8%, other 12%. The test
was ordered as part of a pneumonia workup in
124 instances (69%). Twenty-eight patients
(15%) had a procalcitonin ordered for
SIRS/possible sepsis, while 29 (16%) had it
ordered for other reasons (e.g., leukocytosis,
fever, diarrhea, bleeding, trauma).
Overall antibiotic discordance with the
procalcitonin result was 32% (n = 58). Not
surprisingly, antibiotic discordance was heavily
skewed by initiation or continued use without
de-escalation in patients with low procalcitonin
results. Indeed, 55% of patients with low
procalcitonin results had antibiotics initiated
or continued without de-escalation or
discontinuation. In contrast, antibiotic
discordance was observed in only 9% of
patients with high procalcitonin levels
(Pearson’s Chi-squared p\0.001, Fig. 1).
Among the 50 patients with low procalcitonin
results and discordant antibiotic use, 5 (10%)
had positive microbiologic cultures that may
have affected interpretation of the
procalcitonin test. However, three patients had
non-specific pathogens or amount of growth
from sputum or urine cultures and only two
patients had significant pathogens consistent
with infection (Staphylococcus aureus and
Aspergillus fumigatus from sputum cultures). In
the total study population, the unadjusted odds
ratio of discordant antibiotic use for low versus
high procalcitonin results was 12.5 (95% CI 5.4,
28.8, p\0.001).
Among patients with low procalcitonin
results, provider- but not patient-level factors
were statistically significant in the univariate
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analysis. In this subgroup, critical care services
were more likely than medicine teams to use
antibiotics discordantly (OR 4.43, p = 0.011,
Table 1). Immunocompromised services were
also more likely than medicine services to use
antibiotics discordantly in patients with low
Table 1 Cohort characteristics stratiﬁed by concordant and discordant antibiotic use and unadjusted odds of discordant
antibiotic use, restricted to patients with low procalcitonin results
Cohort characteristics









Average age (years) 60 58 60 60
Female (%) 37.4 39.7 39.8 40.0
Hospitalized in the past 30 days (%) 15.4 22.4 14.6 24.0
Average APR-DRG weighted score 2.9 2.3 2.4 2.3
Average Charlson Comorbidity Index 2.7 2.6 1.7 2.4
Primary service
Medicine (%) 50.4 41.4 75.6 42.0
Critical care (%) 34.2 29.3 12.2 30.0
Transplant (%) 5.7 12.1 0 12.0
Other (%) 9.7 17.2 12.2 16.0
Reason for ordering PCT
Possible pneumonia (%) 65.0 75.9 63.4 76.0
SIRS/possible sepsis (%) 17.1 12.1 7.3 14.0
Other (%) 17.9 12.0 29.3 10.0
Unadjusted odds of discordant antibiotic use, restricted to patients with low procalcitonin results
Variable Odds ratio 95% conﬁdence interval p value
Additional year of patient age 0.99 0.98, 1.02 0.943
Female (vs. male) 1.05 0.45, 2.42 0.925
Hospitalized in the past 30 days (vs. not) 1.84 0.62, 5.44 0.269
Additional unit increase in APR-DRG weighted score 0.99 0.86, 1.15 0.918
Additional unit increase in Charlson comorbidity index 1.23 0.97, 1.56 0.087
Service (reference = medicine)
Critical care 4.43 1.40, 14.04 0.011
Transplant Unable to calculatea
Other 2.36 0.68, 8.22 0.177
Reason for ordering procalcitonin (reference = possible pneumonia)
SIRS/possible sepsis 1.60 0.38, 6.75 0.525
Other 0.29 0.09, 0.91 0.033
APR-DRG All Patient Reﬁned Diagnosis Related Group, PCT procalcitonin, SIRS systemic inﬂammatory response
syndrome
a An odds ratio was unable to be calculated because all patients with low procalcitonin results cared for on an
immunocompromised service continued to receive broad-spectrum antibiotics, making this variable a mathematically perfect
predictor of discordance
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procalcitonin results, although an odds ratio
could not be calculated because all patients
cared for on these services continued to receive
antibiotics without de-escalation. It is important
to note that our guideline did not recommend
testing or use of procalcitonin for
immunocompromised patients, as there were
insufficient data at the time of the study
(including sensitivity, specificity, safety, and
outcome) to recommend its use for those
patients. Variables measuring disease severity
(APR-DRG) and patient complexity (Charlson
Comorbidity Index) were not associated with
increased odds of antibiotic discordance in the
low procalcitonin group (Table 1). Patients with
lowprocalcitoninvalueswhohad the test ordered
because of SIRS/possible sepsis did not have a
statistically significant increase in the unadjusted
odds of antibiotic discordance compared to
patients who had the test ordered as part of a
pneumonia workup. Patients who had the test
ordered for reasons other than possible
pneumonia or sepsis were more likely to have
their antibiotics discontinued or de-escalated.
However, the pre-test probability of infection in
the ‘‘other’’ category was often very low.
A limitation in the current study was the
inability to analyze serial procalcitonin
measurements, which are commonly
performed in septic patients, on concordance.
In our data set, there were less than ten patients
who had serial measurements and all had initial
high procalcitonin levels.
DISCUSSION
The effectiveness of low procalcitonin results to
encourage physicians to withhold, de-escalate,
or discontinue antibiotics in this retrospective
study at a US tertiary care center is lower than
the efficacy reported in predominantly
European clinical trials [5, 6]. Antibiotics were
held, stopped, or de-escalated in less than half
of the patients with low procalcitonin levels
(\0.25 ng/mL), despite its excellent negative
predictive value. Positive cultures could only
account for a small proportion of this
discrepancy. Although our overall
concordance rate was on par with prior
studies, this value is strongly skewed by very
high concordance in patients with elevated
Fig. 1 Antibiotic use in the study population, grouped based on procalcitonin result. PCT procalcitonin
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procalcitonin levels. Future studies examining
the impact of procalcitonin algorithms on
antimicrobial prescribing practices should
consider stratifying their analysis based on
procalcitonin results in addition to reporting
an overall antibiotic concordance rate.
Additionally, we hypothesized that the
severity of the disease or patient complexity
might be a plausible explanation for antibiotic
initiation or lack of de-escalation despite a low
procalcitonin result. Medical care of
hospitalized patients is increasingly complex
in terms of severity of illness on presentation
and comorbidities. However, classic health
services measures of disease severity and
patient complexity were not associated with
increased odds of discordant antibiotic use
among patients with low procalcitonin values
in our study. Moreover, SIRS/possible sepsis was
not significantly associated with discordance in
comparison to lower respiratory tract infection
evaluation. Despite these findings, we did note
that the primary service (critical care and
transplant services) was statistically associated
with increased discordance in the low
procalcitonin group. The combination of these
results indicates that a more complicated
paradigm may be playing a role in antibiotic
prescribing decisions for inpatients.
Provider-level factors, rather than disease
severity or patient complexity, may be an
important variable in the initiation or
continued use of broad-spectrum antibiotics
for patients with low procalcitonin levels.
CONCLUSION
Less than 50% of inpatients with a low
procalcitonin result had their antibiotics held,
de-escalated, or discontinued despite its
excellent negative predictive value. Our study
suggests an important area for continued
research on antimicrobial prescribing practices,
and improved antibiotic stewardship using
procalcitonin should include the use of
behavioral sciences approaches, for example
social psychology and behavioral economic
principles [9–11], in addition to traditional
stewardship interventions such as direct
oversight using prospective audit and feedback
by an antibiotic stewardship team [12–14].
ACKNOWLEDGMENTS
No funding or sponsorship was received for this
study or publication of this article. All named
authors meet the International Committee of
Medical Journal Editors (ICMJE) criteria for
authorship for this manuscript, take
responsibility for the integrity of the work as a
whole, and have given final approval for the
version to be published.
Disclosures. Meghan B. Brennan, Kurt
Osterby, Lucas Schulz, and Alexander J. Lepak
have nothing to disclose.
Compliance with Ethics Guidelines. This
article does not contain any new studies with
human or animal subjects performed by any of
the authors.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommercial
use, distribution, and reproduction in any
medium, provided you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons license, and
indicate if changes were made.
190 Infect Dis Ther (2016) 5:185–191
REFERENCES
1. Becker KL, Nylen ES, White JC, Muller B, Snider RH
Jr. Clinical review 167: procalcitonin and the
calcitonin gene family of peptides in
inflammation, infection, and sepsis: a journey
from calcitonin back to its precursors. J Clin
Endocrinol Metab. 2004;89:1512–25.
2. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P.
Procalcitonin as a diagnostic marker for sepsis: a
systematic review and meta-analysis. Lancet Infect
Dis. 2013;13:426–35.
3. Schuetz P, Chiappa V, Briel M, Greenwald JL.
Procalcitonin algorithms for antibiotic therapy
decisions: a systematic review of randomized
controlled trials and recommendations for clinical
algorithms. Arch Intern Med. 2011;171:1322–31.
4. Soni NJ, Samson DJ, Galaydick JL, Vats V, Pitrak DL,
Aronson N. Procalcitonin-guided antibiotic
therapy. Comparative effectiveness review no. 78.
AHRQ publication no. 12(13)-EHC124-EF.
Rockville, MD: Agency for Healthcare Research
Quality; 2012.
5. Schuetz P, Muller B, Christ-Crain M, Stolz D, Tamm
M, Bouadma L, Luyt CE, Wolff M, Chastre J, Tubach
F, Kristoffersen KB, Burkhardt O, Welte T, Schroeder
S, Nobre V, Wei L, Bhatnagar N, Bucher HC, Briel
M. Procalcitonin to initiate or discontinue
antibiotics in acute respiratory tract infections.
Evid Based Child Health. 2013;8:1297–371.
6. Albrich WC, Dusemund F, Bucher B, Meyer S,
Thomann R, Kuhn F, Bassetti S, Sprenger M,
Bachli E, Sigrist T, Schwietert M, Amin D,
Hausfater P, Carre E, Gaillat J, Schuetz P, Regez K,
Bossart R, Schild U, Mueller B, Pro RST.
Effectiveness and safety of procalcitonin-guided
antibiotic therapy in lower respiratory tract
infections in ‘‘real life’’: an international,
multicenter poststudy survey (ProREAL). Arch
Intern Med. 2012;172:715–22.
7. Foushee JA, Hope NH, Grace EE. Applying
biomarkers to clinical practice: a guide for
utilizing procalcitonin assays. J Antimicrob
Chemother. 2012;67:2560–9.
8. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical
comorbidity index for use with ICD-9-CM
administrative databases. J Clin Epidemiol.
1992;45:613–9.
9. Bayoumi AM, Redelmeier DA. Decision analysis
with cumulative prospect theory. Med Decis
Making. 2000;20:404–12.
10. Persell SD, Friedberg MW, Meeker D, Linder JA, Fox
CR, Goldstein NJ, Shah PD, Knight TK, Doctor JN.
Use of behavioral economics and social psychology
to improve treatment of acute respiratory infections
(BEARI): rationale and design of a cluster
randomized controlled trial [1RC4AG039115-01]—
study protocol and baseline practice and provider
characteristics. BMC Infect Dis. 2013;13:290.
11. Meeker D, Linder JA, Fox CR, Friedberg MW, Persell
SD, Goldstein NJ, Knight TK, Hay JW, Doctor JN.
Effect of behavioral interventions on inappropriate
antibiotic prescribing among primary care
practices: a randomized clinical trial. JAMA.
2016;315:562–70.
12. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr
TT, Andersen MH, Thornberg KJ, Loken J, Steensen
M, Fox Z, Tousi H, Soe-Jensen P, Lauritsen AO,
Strange D, Petersen PL, Reiter N, Hestad S, Thormar
K, Fjeldborg P, Larsen KM, Drenck NE, Ostergaard
C, Kjaer J, Grarup J, Lundgren JD, Procalcitonin
Survival Study. Procalcitonin-guided interventions
against infections to increase early appropriate
antibiotics and improve survival in the intensive
care unit: a randomized trial. Crit Care Med.
2011;39:2048–58.
13. Layios N, Lambermont B, Canivet JL, Morimont P,
Preiser JC, Garweg C, Ledoux D, Frippiat F, Piret S,
Giot JB, Wiesen P, Meuris C, Massion P, Leonard P,
Nys M, Lancellotti P, Chapelle JP, Damas P.
Procalcitonin usefulness for the initiation of
antibiotic treatment in intensive care unit
patients. Crit Care Med. 2012;40:2304–9.
14. Trienski TL, File TM Jr. Implementation of a
procalcitonin assay requires appropriate
stewardship to result in improved antimicrobial
use. Infect Dis Clin Pract. 2015;23:1–2.
Infect Dis Ther (2016) 5:185–191 191
